Found 191 articles
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant scientific initiatives to combat COVID-19: two agreements to develop potential vaccines against SARS-CoV-2, and a research collaboration to advance the development of a novel antiviral candidate. Today’s announcements are: Merck to acquire Themis Bioscience, a company focused on vaccines and immune-modulati
Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature
Vir Biotechnology, Inc. announced the publication of research findings from the company’s efforts to develop therapeutics for COVID-19 in the May 18, 2020 issue of the journal Nature.
Ridgeback Biotherapeutics Announces MHRA Clearance to Begin Human Testing of EIDD-2801 in the UK for COVID-19 and the Start of Phase 1
Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced clearance by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for an orally available antiviral compound, EIDD-2801, to begin human testing. This ac
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
FDA Clears the Way for Ridgeback Biotherapeutics to begin Human Testing of a Promising Potential Treatment for COVID-19
Ridgeback Biotherapeutics LP and Drug Innovations at Emory, LLC, announced that the U.S. Food and Drug Administration has approved an Investigational New Drug application by Drug Innovation Ventures at Emory, LLC, wholly owned by Emory University, for an orally available antiviral compound, EIDD-2801, exclusively licensed to Ridgeback Biotherapeutics, LP, a closely held biotechnology company.
Ridgeback Biotherapeutics LP announced that it has been awarded a contract for $10.9 million to support the development of ansuvimab, an experimental Ebola treatment, though licensure with the U.S. Food and Drug Administration.
Ridgeback Biotherapeutics and Drug Innovations Ventures at Emory Partner to Develop Clinical Stage Coronavirus Treatment
Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory, LLC, a not-for-profit biotechnology company wholly owned by Emory University, announced a collaboration to rapidly advance DRIVE's EIDD-2801, a promising oral COVID-19 treatment, into human testing.
TwinStrand Biosciences™, a novel genetic sequencing technology company, today announced the close of $16 million in Series A funding, including $12 million in new capital. Madrona Venture Group led the investment with participation from Alexandria Venture Investments, Ridgeback Capital and Sahsen Ventures
Ridgeback Biotherapeutics LP announces publication of mAb114 results in the New England Journal of Medicine
Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced that the results for the Pamoja Tulinde Maisha clinical trial have been published in the New England Journal of Medicine.
Ridgeback Biotherapeutics LP announces receipt of Breakthrough Therapy designation from FDA for mAb114
Ridgeback Biotherapeutics LP, a closely held biotechnology company, today announced that the Food and Drug Administration has recently granted mAb114, an experimental treatment for Ebola, Breakthrough Therapy designation.
Ridgeback Biotherapeutics LP, a closely held biotechnology company provides an update on mAb114, an experimental treatment for Ebola.
Ridgeback Biotherapeutics LP, a closely held biotechnology company, today announced that the Food and Drug Administration has recently granted mAb114, an experimental treatment for Ebola, Orphan Drug Designation.
Precision BioSciences announced that it has entered into an agreement for the issuance and sale of convertible promissory notes in a private placement transaction in the aggregate principal amount of approximately $40 million, which will bring the Company’s total capital generated in the last year to over $150 million and total funding since inception to over $300 million.
Ridgeback Biotherapeutics LP announces licensing of mAb114, an experimental Ebola treatment, from the National Institute of Allergy and Infectious Diseases
Ridgeback Biotherapeutics today announced that it has entered into a patent license agreement with the National Institute of Allergy and Infectious Diseases ("NIAID"), part of the National Institutes of Health, for intellectual property related to the monoclonal antibody mAb114, an experimental treatment for Ebola.
Proceeds to Advance Pipeline of Cancer Immunotherapies
4D Molecular Therapeutics snagged $90 million in a Series B financing round. The company intends to use the funds to advance its Therapeutic Vector Evolution platform and pipeline of next-generation AAV gene therapeutics.
4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development announced the closing of its $90 million Series B Financing.
Precision BioSciences closed on an oversubscribed Series B financing worth $110 million. The funds will be used to continue developing its ARCUS genome editing platform.